Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.
| Basel, Switzerland, 14 February 2018 – Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company. This decision advances Lonza’s strategy of being one of the world’s leading, integrated, value-added solutions providers along the healthcare continuum. To further improve its support to customers, Lonza’s Cell- and Gene-Therapy Centers of Excellence will include Lonza sites that are already serving customers and their patients with these innovative technologies. The Lonza sites in Pearland, TX (USA) and Geleen/Maastricht (NL) will offer a fully integrated range of cell- and gene-therapy services including process and analytical development, clinical product supply and commercial product supply. Lonza’s sites in Portsmouth, NH (USA) and Singapore (SG) will serve both as clinical and commercial manufacturing sites. The focus on Cell- and Gene-Therapy Centers of Excellence will shift Lonza’s cell-therapy operations out of Walkersville, MD (USA) and enable the Walkersville site to focus entirely on the Bioscience Solutions business. Through the Lonza Cell- and Gene-Therapy Centers of Excellence, customers will be able to access customer-centric solutions through utilizing: - Expertise from the highly specialized teams concentrated across key locations - Continued proximity with a newly focused global footprint spanning the United States, Europe and Asia - Flexible solutions to support fast-track programs with the integrated offerings “This move is being made to further facilitate the development and transition to commercial production for Lonza customers who are using, or seeking to use, our state-of-art cell- and gene-therapy services,” said Marc Funk, COO Lonza Pharma & Biotech. “We continue to develop sustainable solutions for our customers, whose patients can ultimately benefit from the latest science and technologies in this sector. These therapies are transforming the way patients are treated.” “The refined structure of Lonza’s cell- and gene-therapy business will provide opportunities for customers, patients and employees for both the short- and long-term,” said Andreas Weiler, Head of the Emerging Technologies business unit that manages Lonza’s cell- and gene-therapy offerings. “Our combined offerings provide accelerated market readiness, advanced technologies, flexible business models and global locations so that customers can access the depth and breadth of solutions they need in this fast-moving area of novel and innovative medicines.” Cell and gene therapy is one of the key pillars for Lonza Pharma & Biotech’s overall strategy to deliver the medicines of tomorrow, today. |
| About Lonza Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer’s healthy environment. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources. Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com. Lonza Contact Details For Investor Relations Enquiries: Dirk Oehlers, Head Investor Relations Lonza Group Ltd Tel +41 61 316 8540 For Media Enquiries: Dominik Werner, Head Corporate Communications Lonza Group Ltd Tel +41 61 316 8798 Constance Ward, Head External Communications Lonza Group Ltd Tel +41 61 316 8840 For Media Enquiries in North America: Melanie Waldman, Global Director Strategic Communications Lonza Group Ltd +1 845 537 9101 Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release. |
